Access links:
CONTENT
Destacados
Research
- Actiu
CUTHIVAC Cutaneous HIV Vaccination
The CUT’HIVAC project is an innovative needle-free vaccination strategy across the skin to combat HIV and other infectious diseases.
Funded by the European...
Financing entity: European Comission
Participant entities: Universite Pierre et Marie Curie, University of Regensburg, FIT Biotech Oy Ltd, CHARITE, St George’s University of London, MRC Medical Research Council, IMPACTA, Centre National de la Recherche Scientifique, INSERM, Instituto Nacional de Saúde, GENEART AG, NOVAMEN
Date: 01/01/2010
Research Supervisor(s): Christian Brander
- Actiu
Natural prevalence of HCV variants with decreased sensitivity to NS3/4A protease inhibitors in HIV-1 co-infected patients treated with interferon (peg-INF) plus ribavirin (RBV)
Financing entity: Merck Sharp & Dohme
Participant entities: Fundació IrsiCaixa
Date: 01/10/2009
- Actiu
Collaborative HIV and Anti-HIV Drug Resistance Network
CHAIN - 223131
Financing entity: European Community Framework –Network of excellence
Participant entities: Fundació IrsiCaixa
Date: 01/04/2009
- Actiu
HIV Coevolution and Drug Resistance
Support for training and career development of researchers (Marie Curie). European Re-integration Grants (ERG) - GRANT AGREEMENT No 238885.
Financing entity: European Community, 7th Framework Programme
Participant entities: Fundació IrsiCaixa
Date: 01/04/2009
- Actiu
Nanoparticulas de acido polilactico recubiertas de antigenos VIH y vectores poxvirus que expresan proteina gag o proteinas reguladoras del ciclo del VIH como inmunogenos para na vacuna contra
SAF2008-04395
Financing entity: Ministerio de Educación y Ciencia
Participant entities:
Date: 01/01/2009
